Podcasts about renal cell cancer

Singer-Songwriter Anna Moon is here! Writing the hits alongside her husband, Country Star Niko Moon, we talk motherhood, music , mental health and FOOD! Yep, she is an ace in the kitchen, and we talk about it all! Bringing positive vibes to each day, Anna is here to inspire you to bring your best to everyday and give yourself some grace along the way."And the moon said to me, "My darling you do not have to be whole in order to shine."-LKShow Notes:Follow: Anna Moon (@annamoon) • Instagram photos and videosMental Health: HAPPY COWBOY FOUNDATION (@happycowboyfoundation) • Instagram photos and videosLearn more: Hereditary Leiomyomatosis and Renal Cell Cancer (hlrcc.org)New Album Better Days-out 1/19:  Home - Niko MoonJoin Life and Wellness Coach, Kira Mesi as she navigates the ups and downs of life through personal experience, storytelling, and interviews. Learn to lean into your best self with the mindful practice of gratitude living, honoring your soul's purpose, and the joy of Finding Rainbows on an ordinary day."Dive into the ordinary looking for the extraordinary because life is hard, but if you look close enough, you will find the Rainbows." ~Kira*Schedule your Free Online Life Coaching Consultation with me and start creating a life you love today!Who am I? • @findingrainbows • Milkshake Website Builder (msha.ke)Smile Sciences: Discount Code: FindingrainbowsBuy Cruelty Free Teeth Whitening Products – Smile SciencesSHOP OUR RAINBOWS STORE AND SUPPORT THE PODCASTFinding Rainbows The Podcast (finding-rainbows-the-podcast.myshopify.com)*Grab our bestselling hoodie and support a worthy cause!LOVE IS THE ANSWER! Our bestselling hoodie is not only a work of art b – Finding Rainbows The Podcast (finding-rainbows-the-podcast.myshopify.com)*All proceeds of the Love is the answer" hoodie to: Meals By GraceFOLLOW ME FOR MORE INSPIRATION:@FindingRainbows | LinktreeSupport the showSupport the showCreate a LIFE you LOVE!

- Overview of Renal Cell Cancer, in the Context of COVID, Omicron & Seasonal Flu - Current Standard of Care for Early Stage Renal Cell Cancer - Treatments for Metastatic Renal Cell Cancer - New Treatment Approaches - Targeted Cancer Therapies - The Role of Clinical Trials - How Research Contributes to Your Treatment Options - Managing Side Effects, Symptoms, Discomfort & Pain - Nutrition & Hydration Concerns & Tips - Guidelines to Prepare for Telehealth/Telemedicine Appointments, including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team about Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Renal Cell Cancer, in the Context of COVID, Omicron & Seasonal Flu - Current Standard of Care for Early Stage Renal Cell Cancer - Treatments for Metastatic Renal Cell Cancer - New Treatment Approaches - Targeted Cancer Therapies - The Role of Clinical Trials - How Research Contributes to Your Treatment Options - Managing Side Effects, Symptoms, Discomfort & Pain - Nutrition & Hydration Concerns & Tips - Guidelines to Prepare for Telehealth/Telemedicine Appointments, including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team about Quality-of-Life Concerns - Questions for Our Panel of Experts

Discussing the management using the algorithm of Kidney Cancer or Renal Cell Cancer (RCC) – with Dr. Elizabeth Plimack, Deputy Director, Fox Chase Cancer Center – Temple Health, Director – Genitourinary Clinical Research, Temple University Health System. Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com  

Bob Figlin, MD, and Toni Choueiri, MD, the director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, discuss the early results from the COSMIC-313 trial, which Dr. Choueiri presented at ESMO 2022. The trial enrolled previously untreated patients with metastatic clear cell renal cell cancer who were classified as intermediate- to poor-risk. Standard of care doublet therapy, nivolumab (nivo) plus ipilimumab (ipi), was compared with triplet therapy, consisting of nivo-ipi plus cabozantinib. Triplet therapy improved progression-free survival compared with doublet therapy, specifically in the intermediate-risk group. Dr. Choueiri also discussed the complicated landscape in RCC and how practicing oncologists can evaluate patients for appropriate treatments as well as how to communicate effectively with patients about the factors that contribute to that decision.

Es wird wieder hochurologisch bei den Katheterkollegen! Dr. Stefanie Zschäbitz (OÄ Innere, Heidelberg) und Dr. Eva Erne (OÄ Urologie, Tübingen) bringen Ordnung ins Nierenzellkarzinom-Wirrwarr: “Welcher Patient bekommt welche Immuntherapie?”, “Über welche Nebenwirkungen muss ich den Patienten aufklären?” und “Welche Untersuchungen brauche ich eigentlich, bevor ich eine Immuntherapie starten kann?”. Antworten auf all diese Fragen gibt's in dieser Folge - viel Spaß beim Zuhören!

Subscribe to Blood & Cancer: Apple Podcasts, Spotify, Google Podcasts   This week in HemOnc News: Higher death rate seen in cancer patients with nosocomial COVID-19 Article: https://bit.ly/2XjRLDq Source: https://bit.ly/3goLGgF Robotic renal surgery bests open partial nephrectomy Article: https://bit.ly/2PhHS4MSource: https://bit.ly/3gqXXBd Large cohort study: Bevacizumab safe, effective for severe HHT bleeds Article: https://bit.ly/2XpuZdjSource: https://bit.ly/2BXHVQg For more MDedge Podcasts, click this link: http://bit.ly/2CfnY52   Email the show: podcasts@mdedge.com   Follow Dr. David Henry on Twitter @DavidHenryMD  

Dr. Jayanthi Vijayakumar, oncologist with the Minnesota Oncology & Ridgeview cancer and Infusion Center, discusses renal cancer, including differentiating renal cancer from other forms of cancer, and evidence-based national guidelines used in the treatment of renal cancer. Objectives: Upon completion of this CME event, program participants will be able to: Differentiate kidney cancer from other cancer types. Understand and describe AJCC staging in clinical practice. Identify appropriate prognostic indicators. Identify evidence-based national guidelines (NCC) used in treatment of kidney cancer. CME credit is only offered to Ridgeview Providers for this podcast activity. Complete and submit the online evaluation form, after viewing the activity.  Upon successful completion of the evaluation, you will be e-mailed a certificate of completion within 2 weeks.  You may contact the accredited provider with questions regarding this program at rmccredentialing@ridgeviewmedical.org. Click on the following link for your CME credit:  CME Evaluation: Metastatic Renal Cell Cancer Management - CME Enduring Activity (**If you are listening to the podcasts through iTunes on your laptop or desktop, it is not possible to link directly with the CME Evaluation for unclear reasons. We are trying to remedy this. You can, however, link to the survey through the Podcasts app on your Apple and other smart devices, as well as through Spotify, Stitcher and other podcast directory apps and on your computer browser at these websites. We apologize for the inconvenience.)  The information provided through this and all Ridgeview podcasts as well as any and all accompanying files, images, videos and documents is/are for CME/CE and other institutional learning and communication purposes only and is/are not meant to substitute for the independent medical judgment of a physician, healthcare provider or other healthcare personnel relative to diagnostic and treatment options of a specific patient's medical condition.”   FACULTY DISCLOSURE ANNOUNCEMENT  It is our intent that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It is not assumed any potential conflicts will have an adverse impact on these presentations. It remains for the audience to determine whether the speaker’s outside interest may reflect a possible bias, either the exposition or the conclusions presented. Planning committee members and presenter(s) have disclosed they have no significant financial relationship with a pharmaceutical company and have disclosed that no conflict of interest exists with the presentation/educational event.

MUNICH—A leading European oncologist acknowledged the impressive life-extending potential of new drug combinations for metastatic renal cell carcinoma discussed at the 2018 annual congress of the European Society for Medical Oncology (ESMO). Progress was reported with purely immunological approaches—using two …John Haanen Audio Journal of Oncology

MUNICH— A doubling of progression free survival (PFS) and objective response rate (ORR) was observed in patients who had their previously untreated advanced renal cell cancer (RCC) treated with a combination of the vascular endothelial growth factor (VEGF) inhibitor axitinib …Robert Motzer ESMO AJO

FDA medical oncologists discuss the November 2017 approval of sunitinib for the adjuvant treatment of patients with renal cell carcinoma who are at high risk of recurrence following a nephrectomy.

Samra Turajlic discusses the contribution of small insertions and deletions to tumour-specific antigen analyses.

Dr Choueiri talks to ecancertv at the ASCO GU 2016, about a study looking at associations between analgesic use and risk of renal cell cancer overall and by subtypes, taking data from both the Nurses’ Health Study (NHS) and the Health Professionals Follow-up Study (HPFS). The findings support a significant positive association between non-aspirin NSAID use and risk of developing renal cell cancer, especially the lethal form.

Renal Cell Cancer and the General Medical Oncologist: Where We Are and Where We're Headed. Proceedings from a Clinical Investigator Think Tank featuring Robert A Figlin, MD, Thomas E Hutson, DO, PharmD, David F McDermott, MD, Robert J Motzer, MD, David I Quinn, MBBS, PhD and Walter Stadler, MD. Moderated by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.

Renal Cell Cancer and the General Medical Oncologist: Where We Are and Where We're Headed. Proceedings from a Clinical Investigator Think Tank featuring Robert A Figlin, MD, Thomas E Hutson, DO, PharmD, David F McDermott, MD, Robert J Motzer, MD, David I Quinn, MBBS, PhD and Walter Stadler, MD. Moderated by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/RCCUSE10 –Renal Cell Cancer Update - Practical Considerations in the Management of Renal Cell Cancer. Proceedings from a Case-Based CME Symposium moderated by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.

ResearchToPractice.com/RCCUSE10 –Renal Cell Cancer Update - Practical Considerations in the Management of Renal Cell Cancer. Proceedings from a Case-Based CME Symposium moderated by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/RCCUSE10 – Renal Cell Cancer Update - Practical Considerations in the Management of Renal Cell Cancer. Roundtable discussion with Ronald M Bukowski, MD and Daniel J George, MD moderated by Neil Love, MD. Produced by Research To Practice.